SRC and brain neoplasm: With kinome profiling we previously identified vascular endothelial growth factor receptor 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFRβ), Src, the epidermal growth factor receptor family (ErbB1-4), and hepatocyte growth factor receptor (HGFR/cMet) as potentially drugable targets in these pediatric brain tumors.[5] Potential interesting inhibitors for these targets are sorafenib, dasatinib, canertinib and crizotinib respectively (overview in Fig. 1).